Company intelligence / Profile preview

Shuttle Health

Gaithersburg, Maryland, United Statesshuttle.health ↗

Ownership: Private
Development stage: Commercial

Overview

The lead candidate, Ropidoxuridine, is in a Phase 2 trial for glioblastoma patients undergoing radiation therapy. The trial has enrolled 16 of an initial 40 patients, with half completing all seven cycles. Preclinical work continues on selective histone deacetylase inhibitors and PSMA-targeted theranostic agents for prostate cancer. The company also develops predictive biomarker diagnostics for treatment planning in prostate cancer.

Therapeutic areas: Oncology
Modalities: Small moleculeBiologic (for diagnostic/theranostic ligands)
Industry: Biotech

Partnerships

University of California San Francisco (UCSF) – research agreement for PSMA-targeted ligand developmentTheradex Oncology – CRO partnerTCG GreenChem – manufacturing partner

Beyond the preview

Go deeper on Shuttle Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shuttle Health.

Explore the full profile